News

Open letter supporting Italy’s proposed resolution on Improving the transparency of markets for drugs, vaccines and other health-related technologies

On February 1, 2019, the government of Italy submitted the text of draft resolution to the WHO, with a cover letter noting the aim of providing an “authoritative mandate to strengthen WHO’s technical work on the transparency of the costs of research and development and the transparency of prices” for discussion under agenda item 11.7 […]

Putting People’s Health First: Improving Access to Medicines in Europe

Putting People’s Health First: Improving Access to Medicines in Europe – November 2018 Download the European Elections Manifesto “Putting People’s Health First: Improving Access to Medicines in Europe” The Manifesto is also available in French, Spanish, Gaelic, Dutch, Greek Health and R&D policies are a critical to the success of the European project. In order to put […]

Civil society position on the proposal of the European Commission for the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver

Civil society position on the proposal of the European Commission for the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver As civil society organisations working on access to medicines and public health, we wish to contribute to the ongoing discussions on the European Commission proposal for the introduction of an SPC manufacturing waiver. European […]

Public Return on Public Investment: ensuring sustainable societal impact of EU-funded biomedical Research and Innovation

Civil society’s proposal for Horizon Europe, the next EU research framework programme Read and download the full proposal here September 2018 High prices of new drugs for cancer, hepatitis C and rare diseases in Europe have attracted great media and public attention and have brought the debate about access to medicines into the political spotlight […]

Ensuring EU funded medical R&I delivers for EU citizens and beyond

Civil society reaction to the European Commission’s proposal on Horizon Europe We, the undersigned twenty one civil society organisations, raise our strong concern about the European Commission proposal on the next research framework programme Horizon Europe which fails to make a serious commitment to ensure public interest-driven biomedical R&I. Though the challenge of access to […]

Thirty-five groups write to Commissioner Malmström expressing concerns over the European Commission’s plans to create an EU Watch List

On 16th April 2018, 35 civil society groups wrote a letter to the European Commissioner for Trade, Cecilia Malmström, expressing concerns over the European Commission’s plans to create an EU Watch List. The letter states that “despite the European Union’s public pledge of support for third countries’ right to use the flexibilities of the TRIPS Agreement and […]

Open letter in reaction to Council Conclusions “From the Interim Evaluation of Horizon 2020 towards the 9th Framework Programme”

To: Mr. Carlos Moedas, Commissioner for Research, Science and Innovation Cc: Mr. Vytenis Andriukaitis, Commissioner for Health and Food Safety        Permanent Representations to the EU 4th December 2017 Open letter in reaction to Council Conclusions “From the Interim Evaluation of Horizon 2020 towards the 9th Framework Programme” As civil society organisations working […]

Open letter to the European Commission on the follow-up of the June 2016 EU Council Conclusions

Open letter to the European Commission on the follow-up of the June 2016 EU Council Conclusions on “Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States” On 17 June, 2016, all 28 European Union (EU) Health Ministers agreed on Council Conclusions to address the imbalances in the pharmaceutical systems in […]

Adaptive pathways: concerns are not swiped away by EMA’s report

On 3rd August the European Medicines Agencies published the long-awaited report on its so-called adaptive pathways pilot project. The report did not dissipate the doubts on the approach raised by civil society organisations, academics and HTAs. A clear definition of unmet medical needs, well-defined criteria to assess drugs to enter a fast-tracking market approval, more transparency, […]

“Dying at these prices: generic HCV cure denied”: the 2nd mapCrowd’s report

On World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) launched a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at mapCrowd.org. The report offers a very good overview and data on the current situation as well as possible solutions […]